STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity

Combining different immunotherapy approaches is currently building the future of immunotherapy, with the view to maximize anti-tumoral efficacy for larger patient population. The KISIMA™ platform allows the development of protein-based cancer vaccines able to induce tumor-specific T cell response re...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Front Immunol
Päätekijät: Rossi, Matteo, Carboni, Susanna, Di Berardino-Besson, Wilma, Riva, Erika, Santiago-Raber, Marie-Laure, Belnoue, Elodie, Derouazi, Madiha
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2021
Aiheet:
Immunology
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8283310/
https://ncbi.nlm.nih.gov/pubmed/34276686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.695056
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia